Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have colorectal cancer that cannot be removed by surgery or has spread to other parts of the body, and you have already received at least one previous cancer treatment
- You have advanced or metastatic pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), and you have already received at least one previous cancer treatment
- You have advanced and/or inoperable biliary tract cancer (cancer affecting the bile ducts or gallbladder), and you have already received at least one previous cancer treatment
- You have advanced and/or inoperable biliary tract cancer and have not yet received any previous cancer treatment
- If you have had prior cancer treatment, any side effects from that treatment have cleared up or resolved before joining the trial
Who may not be able to join:
- You have a history of serious eye disease
- You have received any systemic (whole-body) cancer treatment — including experimental treatments — within the last 4 weeks before the trial would begin (confirm with trial site)
- You have a history of non-infectious lung inflammation (pneumonitis or interstitial lung disease) that required steroid treatment, currently have this condition, or have suspected lung inflammation that cannot be ruled out by standard tests at the screening stage
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Australian sites
+61288908935
+61736467712
+61394268996
+61397848152
+61862799466
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants Who Experience a Dose-limiting Toxicity (DLT); Number of Participants Who Experience One or More Adverse Events (AEs); Number of Participants who Discontinue Study Treatment due to an AE; Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.